Dismissal Of Investor Suit Over Drug Maker’s Diabetes Drug Statements Affirmed
NEW ORLEANS — A Fifth Circuit U.S. Court of Appeals panel on Sept. 10 affirmed a lower court’s holding that dismissed shareholder claims against a biopharmaceutical company and certain of its...To view the full article, register now.
Already a subscriber? Click here to view full article